Oxidative status and prevalent cardiovascular disease in patients with chronic renal failure treated by hemodialysis

Clinical Nephrology

Volumn 68, Issue 3, 2007, Pages 144-150

  Dirican, M ^a   Sarandol, E ^a   Serdar, Z ^a   Ocak, N ^a   Dilek, K ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Cardiovascular disease; Hemodialysis; Malondialdehyde; Oxidative status; Paraoxonase activity

Indexed keywords

ALBUMIN; ALPHA TOCOPHEROL; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; ASCORBIC ACID; CAROTENOID; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; SUPEROXIDE DISMUTASE; URIC ACID;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CELL LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEMODIALYSIS; HUMAN; INCIDENCE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PREVALENCE; URIC ACID BLOOD LEVEL; VITAMIN BLOOD LEVEL;

EID: 34548528955     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp68144     Document Type: Article

References (42)

1. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993; 21: 573-592.
2. Boaz M, Matas Z, Biro A, Katzir Z et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int. 1999; 56: 1078-1083.
3. Buege JA, Aust SD. Microsomal lipid peroxidation, Methods Enzymol. 1978; 52: 302-310.
4. Canestrari F, Galli F, Giorgini A, et al. Erythrocyte redox state in uremic anemia: effects of haemodialysis and relevance of glutathione metabolism. Acta Haematol. 1994; 91: 187-193.
5. Clermont G, Lecour S, Lahet J et al. Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res. 2000; 47: 618-623.
6. Cristol JP, Canaud B, Rabesandratana H et al. Enhancement of reactive oxygen species production and cell surface markers expression due to haemodialysis. Nephrol Dial Transplant. 1994; 9: 389-394.
7. Danielski M, Ikizler TA, McMonagle E et al. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance haemodialysis therapy. Am J Kidney Dis. 2003; 42: 286-294.
8. Dantoine TF, Debord J, Charmes JP et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol. 1998; 9: 2082-2088.
9. Dirican M, Akca R, Sarandol E et al. Serum paraoxonase activity in uremic predialysis and haemodialysis patients. J Nephrol. 2004; 17: 813-818.
10. Durak I, Akyol O, Basesme E et al. Reduced erythrocyte defense mechanisms against free radical toxicity in patients with chronic renal failure. Nephron. 1994; 66: 76-80.
11. Eckerson HW, Wyte MC, La Du BN. The human serum paraoxonase/ arylesterase polymorphism. Am J Hum Genet. 1983; 35: 1126-1138.
12. Fairbanks V, Klee GG. Biochemical aspects of haematology. In: Burtis CA, Ashwood ER (eds). Tietz Textbook of Clinical Chemistry. Philadelphia: W.B. Saunders; 1994. pp. 2020-2021.
13. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998; 9: S16-S23.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-508.
15. Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem. 1992; 30: 391-395.
16. Halliwell B. Albumin - an important extracellular anti-oxidant? Biochem Pharmacol. 1998; 37: 569-571.
17. Jung HH, Choi DH, Lee SH. Serum malondialdehyde and coronary artery disease in haemodialysis patients. Am J Nephrol. 2004; 24: 537-542.
18. Klemm A, Voigt C, Friedrich M et al. Determination of erythrocyte antioxidant capacity in haemodialysis patients using electron paramagnetic resonance. Nephrol Dial Transplant. 2001; 16: 2166-2171.
19. Levey AS, Eknoyan G. Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant. 1999; 14: 828-833.
20. Loughrey CM, Young IS, McEneny J et al. Oxidation of low density lipoprotein in patients on regular hemodialysis. Atherosclerosis. 1994; 110: 85-193.
21. Lucchi L, Bergamini S, Iannone A et al. Erythrocyte susceptibility to oxidative stress in chronic renal failure patients under different substitutive treatments. Artif Organs. 2005; 29: 67-72.
22. Maggi E, Bellazzi R, Falaschi F et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int. 1994; 45: 876-883.
23. McCormick DB, Greene HL. Vitamins. In: Burtis CA, Ashwood ER (eds). Tietz Textbook of Clinical Chemistry. Philadelphia: W.B. Saunders; pp. 1313-1314.
24. McEneny J, Loughrey CM, McNamee PT et al. Susceptibility of VLDL to oxidation in patients on regular haemodialysis. Atherosclerosis. 1997; 129: 215-220.
25. Miguel A, Miguel A, Linares M et al. Evidence of an increased susceptibility to lipid peroxidation in RBC of chronic renal failure patients. Nephron. 1998; 50: 64-65.
26. Mosca L, Rubenfire M, Tarshis T et al. Clinical predictors of oxidized low-density lipoprotein in patients with coronary artery disease. Am J Cardiol. 1997; 80: 825-830.
27. Neeld JB, Pearson WN. Macro- and micro-methods for the determination of serum vitamin A using trifluoro-acetic acid. J Nutr. 1963; 79: 454-462.
28. Nguyen-Khoa T, Massy ZA, De Brandt JP et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Thansplant. 2001; 16: 335-340.
29. Ozden M, Maral H, Akaydin D et al. Erythrocyte glutathione peroxidase activity, plasma malondialdehyde and erythrocyte glutathione levels in haemodialysis and CAPD patients. Clin Biochem. 2002; 35: 269-273.
30. Suehiro T, Ikeda Y, Shiinoki T et al. Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb. 2002; 9: 133-138.
31. Stocks J, Offerman EL, Modell CB et al. The susceptibility to autoxidation of human red cell lipids in health and disease. Br J Haematol. 1972; 23: 713-724.
32. Sutherland WH, Walker RJ, Ball MJ et al. Oxidation of low-density lipoproteins from patients with renal failure or renal transplants. Kidney Int. 1995; 48: 227-236.
33. Takenaka T, Takahashi K, Kobayashi T et al. Oxidized low-density lipoprotein (Ox-LDL) as a marker of atherosclerosis in haemodialysis (HD) patients. Clin Nephrol. 2002; 58: 33-37.
34. Teissier E, Walters-Laport E, Duhem C et al. Rapid quantification of α tocopherol in plasma and low- and high-density lipoproteins. Clin Chem. 1996; 42: 430-435.
35. Usberti M, Gerardi GM, Gazzotti RM et al. Oxidative stress and cardiovascular disease in dialyzed patients. Nephron. 2002; 91: 25-33.
36. Van Lenten BJ, Wagner AJ, Navab M et al. Oxidized phospholipids induce changes in hepatic paraoxonase and Apo J but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem. 2001; 276: 1923-1929.
37. Westhuyzen J, Saltissi D, Healy H. Oxidation of low-density lipoprotein in haemodialysis patients: effect of dialysis and comparison with matched controls. Atherosclerosis. 1997; 129: 199-205.
38. Yamamoto Y, Sakata N, Meng J et al. Possible involvement of increased glycoxidation and lipid peroxidation of elastin in atherogenesis in haemodialysis patients. Nephrol Dial Transplant. 2002; 17: 630-636.
39. Young IS, Trimble ER. Measurement of malondialdehyde in plasma by high-performance liquid chromatography with fluorimetric detection. Ann Clin Biochem. 1991; 28: 504-508.
40. Zachee P, Ferrant A, Daelemans R et al. Oxidative injury to erythrocytes, cell rigidity and splenic haemolysis in hemodialyzed patients before and during erythropoietin treatment. Nephron. 1993; 65: 88-293.
41. Zhang A, Vertommen J, Van Gaal L et al. A rapid and simple method for measuring the susceptibility of low-density lipoprotein and very low-density lipoprotein to copper-catalyzed oxidation. Clin Chim Acta. 1993; 227: 159-173.
42. Zoccali C. Cardiovascular risk in ureamic patients - is it fully explained by classical risk factors? Nephrol Dial Transplant. 2000; 15: 454-457.